• linkedin
  • Increase Font
  • Sharebar

    Suprachoroidal corticosteroid shows visual, anatomic improvements in DME eyes

     

    HULK trial outlined

    HULK trial was an investigator-initiated multicenter trial that enrolled a total of 20 patients, of which 50% were treatment naïve and the other 50% had been previously treated. All treatment-naïve patients received intravitreal aflibercept 2 mg (Eylea, Regeneron) at baseline in addition to CLS-TA. The previously treated group had received an average of 23 prior treatments, which were comprised primarily of intravitreal injections with an anti-VEGF agent or corticosteroid, and received CLS-TA only.

    Beginning at 2 months, all patients were eligible to receive suprachoroidal CLS-TA injection as needed (prn) if central retinal thickness (CRT) was >320 µm and not improved by at least 20% from the prior 2 visits.

    At baseline, mean best corrected visual acuity (BCVA) was about 20/50 in both the treatment-naïve and previously treated arms. Mean CRT in the previously treated group was thicker than in the treatment-naïve eyes, 483 µm versus 442 µm.

    The study had good retention and compliance. A single patient withdrew at month 4 and overall, less than 4% of scheduled visits were missed.
    The eligibility criteria for retreatment were met for 53% of the 74 possible prn retreatments. In the previously treated and treatment-naive arms, retreatment was delivered for 61% and 44% of possible retreatments, respectively.  Mean number of CLS-TA injections given over the 6-month trial was 3, and 50% of patients required either no or just 1 retreatment.

     

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';